Phase I Study of Erbitux (Cetuximab) in Pediatric Patients With Refractory Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 25 Nov 2015
At a glance
- Drugs Cetuximab (Primary) ; Irinotecan
- Indications Non-Hodgkin's lymphoma; Solid tumours
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 15 May 2008 Planned patient number changed from 60 to 48, reported by ClinicalTrials.gov.
- 15 May 2008 Status changed from in progress to completed, reported by ClinicalTrials.gov.
- 11 Mar 2008 Status changed from recruiting to in progress.